CU6 — Clarity Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- AU$685.88m
- AU$647.90m
- 30
- 16
- 90
- 45
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Depreciation and Amortization | ||||
Other Operating Expenses | ||||
Total Operating Expenses | 7.36 | 10.3 | 23.8 | 26.4 |
Operating Profit | -7.36 | -10.3 | -23.8 | -26.4 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -6.95 | -10.2 | -23.7 | -24.5 |
Provision for Income Taxes | ||||
Net Income After Taxes | -6.95 | -10.2 | -23.8 | -24.6 |
Net Income Before Extraordinary Items | ||||
Net Income | -6.95 | -10.2 | -23.8 | -24.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -6.95 | -10.2 | -23.8 | -24.6 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.027 | -0.04 | -0.096 | -0.094 |
Dividends per Share |